Q2 EPS Forecast for Cogent Biosciences Increased by Analyst

Cogent Biosciences, Inc. (NASDAQ:COGT) – Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for Cogent Biosciences in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the technology company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.64). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS and FY2027 earnings at $1.13 EPS.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Several other equities research analysts have also recently commented on the company. Scotiabank assumed coverage on Cogent Biosciences in a research report on Friday, March 7th. They set a “sector outperform” rating and a $17.00 price objective on the stock. HC Wainwright lowered their price objective on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a research report on Friday, March 7th. Robert W. Baird lowered their price target on Cogent Biosciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research note on Tuesday, February 25th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.29.

Cogent Biosciences Price Performance

Shares of NASDAQ:COGT opened at $5.13 on Monday. Cogent Biosciences has a 1-year low of $3.72 and a 1-year high of $12.61. The company has a market capitalization of $584.08 million, a PE ratio of -2.07 and a beta of 1.91. The business has a fifty day moving average price of $5.60 and a 200-day moving average price of $7.65.

Institutional Trading of Cogent Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC increased its stake in Cogent Biosciences by 11,869.9% in the first quarter. CWM LLC now owns 8,738 shares of the technology company’s stock worth $52,000 after purchasing an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Cogent Biosciences during the fourth quarter valued at about $78,000. Hsbc Holdings PLC bought a new stake in Cogent Biosciences during the fourth quarter valued at about $81,000. KLP Kapitalforvaltning AS bought a new stake in Cogent Biosciences during the fourth quarter valued at about $88,000. Finally, E Fund Management Co. Ltd. bought a new stake in Cogent Biosciences during the fourth quarter valued at about $89,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.